NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto

Michael Untch,Christian Jackisch,Andreas Schneeweiss,S Schmatloch,Bahriye Aktas,Carsten Denkert,Christian Schem,Hermann Wiebringhaus,Sherko Kümmel,Mathias Warm,Peter A. Fasching,Marianne Just,Claus Hanusch,John Hackmann,Jens-Uwe Blohmer,Kerstin Rhiem,Wolfgang D. Schmitt,Jenny Furlanetto,Bernd Gerber,Jens Huober,Valentina Nekljudova,Gunter von Minckwitz,Sibylle Loibl

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto

2019

PURPOSEThe GeparSepto trial demonstrated that weekly nanoparticle albumin-bound ( NAB)– paclitaxelsignificantly improves the pathologic complete remission rate compared with weekly solvent-based (sb...

Keywords:

Nab-paclitaxel
Breast cancer
Disease
Pathologic Complete Remission
Oncology
Pathology
Medicine
Internal medicine
disease free survival
early breast cancer

Correction
Source
Cite
Save

References

Citations